Related Experiment Video
Updated: Sep 12, 2025
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Unravelling Osteoporosis: Key Genes and Potential Therapies
Huichao Fu1, Yunjiao Wu2, Hongfei Lv1
1Department of Orthopedic Surgery, Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, China.
Abstract:
Osteoporosis is a metabolic bone disease characterised by decreased bone mass and increased fracture risk, especially in aging women. Current treatments have limitations and side effects, prompting the need for novel therapeutic targets. Using Mendelian randomisation (MR) on the basis of GWAS data from the FinnGen consortium, we identified druggable genes associated with osteoporosis. Transcriptomic profiling, single-cell RNA sequencing (scRNA-seq) and immune infiltration analysis were employed to explore gene expression patterns and immune relevance. Gene set enrichment analysis and gene set variation analysis were used to investigate related signalling pathways. Three genes-FMO4, PSMA4 and VEGFA-were significantly associated with osteoporosis risk. FMO4 showed a protective association and was enriched in vascular and immune cells, suggesting roles in oxidative stress and microenvironment regulation. PSMA4, involved in proteasome activity, was upregulated in macrophages and T cells, potentially influencing bone remodelling through immune-related protein degradation. VEGFA expression correlated positively with osteoporosis risk, possibly via ER-β-mediated signalling that promotes osteoblast apoptosis. All three genes were involved in key pathways, including calcium signalling, Wnt/β-catenin, PI3K/Akt and Hedgehog signalling. Immune analysis revealed strong associations with dendritic cells and macrophages. This study identifies FMO4, PSMA4 and VEGFA as key genes associated with osteoporosis, analyses their molecular mechanisms and regulatory networks and elucidates their relationship with the disease. Furthermore, it suggests 52 candidate compounds potentially interacting with VEGFA and 8 with PSMA4, offering a basis for further investigation into their therapeutic potential.
Insights
This study identifies FMO4, PSMA4, and VEGFA as key genes linked to osteoporosis risk. These findings offer potential new therapeutic targets for metabolic bone disease treatment.
Area of Science:
- Genetics and Molecular Biology
- Immunology
- Pharmacology
Background:
- Osteoporosis is a prevalent metabolic bone disease causing decreased bone mass and increased fracture risk, particularly in aging women.
- Existing osteoporosis treatments have limitations and side effects, necessitating the identification of novel therapeutic targets.
Purpose of the Study:
- To identify druggable genes associated with osteoporosis using Mendelian randomization (MR) and GWAS data.
- To explore the molecular mechanisms, immune relevance, and signalling pathways of identified osteoporosis-associated genes.
- To suggest potential therapeutic compounds for osteoporosis based on identified gene targets.
Main Methods:
- Mendelian randomization (MR) analysis on GWAS data from the FinnGen consortium.
- Transcriptomic profiling, single-cell RNA sequencing (scRNA-seq), and immune infiltration analysis.
- Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) to investigate signalling pathways.
Main Results:
- Three genes—FMO4, PSMA4, and VEGFA—were significantly associated with osteoporosis risk.
- FMO4 demonstrated a protective association, enriched in vascular and immune cells.
- PSMA4 was upregulated in macrophages and T cells, potentially affecting bone remodelling via immune-related protein degradation.
- VEGFA expression positively correlated with osteoporosis risk, possibly through ER-β-mediated signalling promoting osteoblast apoptosis.
- Identified genes are involved in calcium signalling, Wnt/β-catenin, PI3K/Akt, and Hedgehog signalling pathways.
- Immune analysis revealed strong associations with dendritic cells and macrophages.
- Identified 52 candidate compounds for VEGFA and 8 for PSMA4.
Conclusions:
- FMO4, PSMA4, and VEGFA are key genes implicated in osteoporosis pathogenesis.
- These genes are linked to critical signalling pathways and immune cell interactions relevant to bone metabolism.
- The study provides a foundation for developing novel osteoporosis therapeutics targeting these genes and associated pathways.
Related Concept Videos
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Osteoclasts in Bone Remodeling
01:40Bone Remodeling
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: